{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:45:54Z","timestamp":1788583554035,"version":"build-2803163510"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,23]]},"abstract":"<jats:p>Type 2 diabetes mellitus (T2DM) is frequently complicated by dyslipidemia, which increases the cardiovascular risk. Although guidelines strongly recommend lipid-lowering therapy, real-world treatment thresholds and adherence remain inconsistent in the literature. This retrospective observational study included 1001 patients with T2DM who attended outpatient clinics between March 2024 and March 2025. Demographic characteristics, metabolic parameters, and medication use (statins, fibrates, insulin, and neuropathy drugs) were retrieved from the hospital records. Group comparisons were performed using parametric and nonparametric tests, and multivariate logistic regression was used to identify the independent predictors of drug use. The mean age of the cohort was 60.9\u2005\u00b1\u200511.4 years, and 57.1% of the patients were female. The mean HbA1c was 7.47\u2005\u00b1\u20051.56%, low-density lipoprotein (LDL) was 110.7\u2005\u00b1\u200542.8\u2009mg\/dL, high-density lipoprotein was 49.6\u2005\u00b1\u200514.0\u2009mg\/dL, and triglycerides (TG) were 172.7\u2005\u00b1\u2005100.1\u2009mg\/dL. Statin users had higher LDL and high-density lipoprotein levels but lower TG levels than nonusers. Fenofibrate users exhibited markedly higher TG levels. Insulin therapy was associated with poorer glycemic control but did not significantly affect the lipid parameters. In logistic regression, statin use was independently predicted by higher HbA1c and LDL levels, whereas fibrate use was predicted by elevated TG levels. Age was the only independent predictor of neuropathic drug use. In this real-world T2DM cohort, the initiation of statins and fibrates did not align with guideline-based thresholds. Statins were prescribed at higher LDL levels, whereas fibrates were reserved for patients with severely elevated TG levels. These findings highlight the persistent gap between guidelines and clinical practice and emphasize the need for strategies to improve lipid management in secondary-care settings.<\/jats:p>","DOI":"10.1097\/md.0000000000047360","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T18:00:30Z","timestamp":1769191230000},"page":"e47360","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Are lipid-lowering therapies used according to the guidelines?: A real-world retrospective study of 1001 patients with type 2 diabetes"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6915-4057","authenticated-orcid":false,"given":"Muhammet Fatih","family":"\u015eahin","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Kestel State Hospital, Bursa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7279-4714","authenticated-orcid":false,"given":"Ali","family":"Erol","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Bursa Y\u00fcksek \u0130htisas Training and Research Hospital, Bursa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9224-996X","authenticated-orcid":false,"given":"G\u00f6khan","family":"Bayrak","sequence":"additional","affiliation":[{"name":"Department of Physiotherapy and Rehabilitation, Mu\u015f Alparslan University, Mu\u015f, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5367-098X","authenticated-orcid":false,"given":"Ali","family":"\u015eahin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Tokat State Hospital, Bursa, T\u00fcrkiye."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20260610","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nrendo.2017.151","article-title":"Global aetiology and epidemiology of type 2 diabetes mellitus and its complications.","volume":"14","author":"Zheng","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"R3-20260610","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00125-018-4711-2","article-title":"Global trends in diabetes complications: a review of current evidence.","volume":"62","author":"Harding","year":"2019","journal-title":"Diabetologia"},{"key":"R4-20260610","first-page":"150","article-title":"Dyslipidemia in type 2 diabetes mellitus.","volume":"5","author":"Mooradian","year":"2009","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"R5-20260610","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1007\/s00125-015-3525-8","article-title":"Pathophysiology of diabetic dyslipidaemia: where are we?","volume":"58","author":"Verg\u00e8s","year":"2015","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"R6-20260610","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.2337\/dc23-Sint","article-title":"Standards of medical care in diabetes\u20142023.","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"R7-20260610","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias.","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"R8-20260610","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(18)31942-1","article-title":"Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomized controlled trials.","volume":"393","year":"2019","journal-title":"Lancet"},{"key":"R9-20260610","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(07)61607-9","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study).","volume":"370","author":"Keech","year":"2007","journal-title":"Lancet"},{"key":"R10-20260610","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus.","volume":"362","year":"2010","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"R11-20260610","first-page":"S101","article-title":"Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors.","volume":"39","author":"Polonsky","year":"2016","journal-title":"Diabetes Care"},{"key":"R12-20260610","first-page":"1061","article-title":"Clinical inertia in the management of type 2 diabetes mellitus: a focused literature review.","volume":"12","author":"Khunti","year":"2021","journal-title":"Diabetes Ther"},{"key":"R13-20260610","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"R14-20260610","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","article-title":"Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial).","volume":"92","author":"Jones","year":"2003","journal-title":"Am J Cardiol"},{"key":"R15-20260610","first-page":"274","article-title":"Discrepancies between statin prescription and lipid control among patients with diabetes in primary care settings.","volume":"22","author":"Liew","year":"2022","journal-title":"BMC Cardiovasc Disord"},{"key":"R16-20260610","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4093\/dmj.2022.0448","article-title":"Lipid management in Korean people with type 2 diabetes mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis consensus statement.","volume":"47","author":"Yang","year":"2023","journal-title":"Diabetes Metab J"},{"key":"R17-20260610","first-page":"200210","article-title":"Evaluating LDL-C control in Indian acute coronary syndrome (ACS) patients-a retrospective real-world study LDL-C control in ACS.","volume":"19","author":"Jain","year":"2023","journal-title":"Int J Cardiol Cardiovasc Risk Prev"},{"key":"R18-20260610","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1001\/jama.2012.13260","article-title":"Trends in lipids and lipoproteins in US adults, 1988\u20132010.","volume":"308","author":"Carroll","year":"2012","journal-title":"JAMA"},{"key":"R19-20260610","doi-asserted-by":"crossref","first-page":"k3359","DOI":"10.1136\/bmj.k3359","article-title":"Statins for prevention of cardiovascular events in a low-risk population with low LDL cholesterol.","volume":"362","author":"Ramos","year":"2018","journal-title":"BMJ"},{"key":"R20-20260610","first-page":"301","article-title":"Cost-effectiveness of statins in African American populations.","volume":"77","author":"Moran","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"R21-20260610","first-page":"71","article-title":"Statin use in primary prevention: current status and future directions.","volume":"22","author":"Nanna","year":"2020","journal-title":"Curr Cardiol Rep"},{"key":"R22-20260610","first-page":"433","article-title":"Trends in lipid-lowering therapy and lipid profiles among patients with diabetes in Korea.","volume":"46","author":"Kim","year":"2022","journal-title":"Diabetes Metab J"},{"key":"R23-20260610","first-page":"135","article-title":"Fibrate therapy and cardiovascular outcomes in Korean patients with diabetes.","volume":"18","author":"Kim","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"R24-20260610","first-page":"111","article-title":"Fibrate use and cardiovascular risk in patients with type 2 diabetes: a nationwide cohort study.","volume":"26","author":"Hong","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"R25-20260610","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/s12933-024-02422-9","article-title":"Fenofibrate to prevent amputation and reduce vascular complications in patients with diabetes: FENO-PREVENT.","volume":"23","author":"Ku","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"R26-20260610","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"R27-20260610","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment.","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"R28-20260610","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes.","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"},{"key":"R29-20260610","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"From the triumvirate to the ominous octet: a new paradigm for the pathogenesis of type 2 diabetes mellitus.","volume":"58","author":"DeFronzo","year":"2009","journal-title":"Diabetes"},{"key":"R30-20260610","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa032782","article-title":"Vascular risk factors and diabetic neuropathy.","volume":"352","author":"Tesfaye","year":"2005","journal-title":"N Engl J Med"},{"key":"R31-20260610","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1474-4422(12)70065-0","article-title":"Diabetic neuropathy: clinical manifestations and current treatments.","volume":"11","author":"Callaghan","year":"2012","journal-title":"Lancet Neurol"},{"key":"R32-20260610","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41572-019-0092-1","article-title":"Diabetic neuropathy.","volume":"5","author":"Feldman","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"R33-20260610","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.2337\/db08-1771","article-title":"Elevated triglycerides correlate with progression of diabetic neuropathy.","volume":"58","author":"Wiggin","year":"2009","journal-title":"Diabetes"},{"key":"R34-20260610","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41574-021-00496-z","article-title":"Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy.","volume":"17","author":"Sloan","year":"2021","journal-title":"Nat Rev Endocrinol"},{"issue":"Suppl 2","key":"R35-20260610","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1529-8027.2012.00391.x","article-title":"Treatments for diabetic neuropathy.","volume":"17","author":"Bril","year":"2012","journal-title":"J Peripher Nerv Syst"},{"key":"R36-20260610","first-page":"CD007543","article-title":"Enhanced glucose control for preventing and treating diabetic neuropathy.","volume":"2012","author":"Callaghan","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"R37-20260610","first-page":"469","article-title":"Can computerized decision support systems improve practitioners\u2019 diagnostic test ordering behavior? A systematic review.","volume":"317","author":"Roshanov","year":"2017","journal-title":"JAMA"},{"key":"R38-20260610","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.pec.2015.11.003","article-title":"Diabetes self-management education for adults with type 2 diabetes mellitus: a systematic review of the effect on glycemic control.","volume":"99","author":"Chrvala","year":"2016","journal-title":"Patient Educ Couns"},{"key":"R39-20260610","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1056\/NEJMoa1003955","article-title":"Collaborative care for patients with depression and chronic illnesses.","volume":"363","author":"Katon","year":"2010","journal-title":"N Engl J Med"},{"key":"R40-20260610","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.3390\/cells11192972","article-title":"PCSK9 inhibition: from current advances to evolving future.","volume":"11","author":"Liu","year":"2022","journal-title":"Cells"},{"key":"R41-20260610","first-page":"2103","article-title":"Socioeconomic risk factors for macrovascular disease in type 1 diabetes mellitus: the EURODIAB study.","volume":"44","author":"Chaturvedi","year":"2001","journal-title":"Diabetologia"},{"key":"R42-20260610","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMra1510059","article-title":"Pragmatic trials.","volume":"375","author":"Ford","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047360","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T10:01:08Z","timestamp":1781085668000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047360","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"2025-09-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}